kynurenine has been researched along with Degenerative Diseases, Central Nervous System in 47 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Quinolinic acid is an N-methyl-D-aspartate receptor agonist, and raised levels in CSF, together with increased levels of inflammatory cytokines, have been reported in mood disorders." | 6.82 | The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases. ( Aaseth, JO; Alexander, J; Hestad, K; Rootwelt, H, 2022) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations." | 6.66 | Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. ( Tanaka, M; Toldi, J; Vécsei, L, 2020) |
| "Neurodegenerative diseases are multifactorial, initiated by a series of the causative complex which develops into a certain clinical picture." | 6.66 | Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway. ( Tanaka, M; Török, N; Vécsei, L, 2020) |
| "Neuroactive metabolites of the kynurenine pathway (KP) of tryptophan degradation have been closely linked to the pathogenesis of several neurodegenerative diseases." | 4.91 | The kynurenine pathway and neurodegenerative disease. ( Giorgini, F; Maddison, DC, 2015) |
| " The second part of the review deals with the kynurenine metabolic pathway, its alterations and their potential association with cellular energy impairment in certain neurodegenerative diseases." | 4.84 | Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. ( Robotka, H; Sas, K; Toldi, J; Vécsei, L, 2007) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "Quinolinic acid is an N-methyl-D-aspartate receptor agonist, and raised levels in CSF, together with increased levels of inflammatory cytokines, have been reported in mood disorders." | 2.82 | The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases. ( Aaseth, JO; Alexander, J; Hestad, K; Rootwelt, H, 2022) |
| "Neurodegenerative disorders are chronic and life-threatening conditions negatively affecting the quality of patients' lives." | 2.72 | Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders. ( Krupa, A; Mor, A; Pawlak, D; Tankiewicz-Kwedlo, A, 2021) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations." | 2.66 | Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. ( Tanaka, M; Toldi, J; Vécsei, L, 2020) |
| "Neurodegenerative diseases are multifactorial, initiated by a series of the causative complex which develops into a certain clinical picture." | 2.66 | Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway. ( Tanaka, M; Török, N; Vécsei, L, 2020) |
| "The kynurenine pathway (KP) plays a critical role in generating cellular energy in the form of nicotinamide adenine dinucleotide (NAD+)." | 2.66 | The kynurenine pathway: a finger in every pie. ( Savitz, J, 2020) |
| "During stress and major depressive disorders, it is generally accepted that inflammation induces an imbalance toward the excitotoxic branch of the TRY/CAT pathway, causing changes in brain connectivity in corticolimbic structures and therefore psychocognitive abnormalities." | 2.61 | The 'Yin' and the 'Yang' of the kynurenine pathway: excitotoxicity and neuroprotection imbalance in stress-induced disorders. ( Barone, P, 2019) |
| "3-Hydroxykynurenine has been largely described as one of these toxic metabolites capable of inducing oxidative damage and cell death; consequently, this metabolite has been hypothesized to play a pivotal role in different neurological and psychiatric disorders." | 2.49 | 3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system. ( Colín-González, AL; Maldonado, PD; Santamaría, A, 2013) |
| "Adenosine is an ubiquitous purine that can protect neurons by suppressing excitatory neurotransmitter release, reducing calcium fluxes and inhibiting NMDA receptors." | 2.44 | Tryptophan, adenosine, neurodegeneration and neuroprotection. ( Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW; Stoy, N, 2007) |
| "L-kynurenine is a central compound of this pathway since it can change to the neuroprotective agent kynurenic acid or to the neurotoxic agent quinolinic acid." | 2.43 | Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. ( Németh, H; Toldi, J; Vécsei, L, 2006) |
| "Studies in Alzheimer's disease (AD) patients confirm KP dyshomeostasis in plasma and cerebrospinal fluid (CSF) which correlates with amyloid-β and tau pathology." | 1.72 | Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β. ( Bourgeat, P; Cespedes, M; Chatterjee, P; Doecke, JD; Fowler, CJ; Guillemin, GJ; Ittner, A; Jacobs, KR; Lim, CK; Lovejoy, DB; Martins, RN; Maruff, P; Masters, CL; Pertile, KK; Rainey-Smith, SR; Rembach, A; Rowe, CC; Rumble, RL; Trounson, B; Villemagne, VL, 2022) |
| "Quinolinic acid (QUIN) is an agonist of the neurotransmitter glutamate (Glu) capable of binding to N-methyl-D-aspartate receptors (NMDAR) increasing glutamatergic signaling." | 1.62 | Caenorhabditis elegans as a model for studies on quinolinic acid-induced NMDAR-dependent glutamatergic disorders. ( Antunes Soares, FA; Aschner, M; Bicca Obetine Baptista, F; Duarte Hartmann, D; Farina Gonçalves, D; Franzen da Silva, A; Lenz Dalla Corte, C; Limana da Silveira, T; Lopes Machado, M; Marafiga Cordeiro, L, 2021) |
| "The kynurenine pathway is a fundamental mechanism of immunosuppression and peripheral tolerance." | 1.42 | Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease. ( Brew, BJ; Brown, DA; de Bie, J; Franco, NF; Guillemin, GJ; Jones, SP; Lim, CK; Sundaram, G; Varney, B, 2015) |
| "L-kynurenine (L-KYN) serves as a substrate for the synthesis of neurotoxic 3-OH-kynurenine (3-OH-KYN) and neuroprotective kynurenic acid (KYNA)." | 1.30 | Kynurenine metabolism in Alzheimer's disease. ( Baran, H; Deecke, L; Jellinger, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.13) | 18.2507 |
| 2000's | 7 (14.89) | 29.6817 |
| 2010's | 19 (40.43) | 24.3611 |
| 2020's | 20 (42.55) | 2.80 |
| Authors | Studies |
|---|---|
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Cespedes, M | 1 |
| Jacobs, KR | 1 |
| Maruff, P | 1 |
| Rembach, A | 1 |
| Fowler, CJ | 1 |
| Trounson, B | 1 |
| Pertile, KK | 1 |
| Rumble, RL | 1 |
| Rainey-Smith, SR | 1 |
| Rowe, CC | 1 |
| Villemagne, VL | 1 |
| Bourgeat, P | 1 |
| Lim, CK | 2 |
| Chatterjee, P | 1 |
| Martins, RN | 1 |
| Ittner, A | 1 |
| Masters, CL | 1 |
| Doecke, JD | 1 |
| Guillemin, GJ | 3 |
| Lovejoy, DB | 1 |
| Majerova, P | 1 |
| Olesova, D | 1 |
| Golisova, G | 1 |
| Buralova, M | 1 |
| Michalicova, A | 1 |
| Vegh, J | 1 |
| Piestansky, J | 1 |
| Bhide, M | 1 |
| Hanes, J | 1 |
| Kovac, A | 1 |
| Hestad, K | 1 |
| Alexander, J | 1 |
| Rootwelt, H | 1 |
| Aaseth, JO | 1 |
| Chen, Y | 1 |
| Zhang, J | 1 |
| Yang, Y | 1 |
| Xiang, K | 1 |
| Li, H | 1 |
| Sun, D | 1 |
| Chen, L | 1 |
| Martins, LB | 1 |
| Silveira, ALM | 1 |
| Teixeira, AL | 1 |
| Shen, H | 1 |
| Xu, X | 1 |
| Bai, Y | 1 |
| Wang, X | 1 |
| Wu, Y | 1 |
| Zhong, J | 1 |
| Wu, Q | 1 |
| Luo, Y | 1 |
| Shang, T | 1 |
| Shen, R | 1 |
| Xi, M | 1 |
| Sun, H | 1 |
| Sheibani, M | 1 |
| Shayan, M | 1 |
| Khalilzadeh, M | 1 |
| Soltani, ZE | 1 |
| Jafari-Sabet, M | 1 |
| Ghasemi, M | 1 |
| Dehpour, AR | 1 |
| Hajihassani, A | 1 |
| Nourazarian, A | 1 |
| Nikanfar, M | 1 |
| Laghousi, D | 1 |
| Khaki-Khatibi, F | 1 |
| Castro-Portuguez, R | 1 |
| Sutphin, GL | 1 |
| Tóth, F | 1 |
| Fülöp, F | 4 |
| Szatmári, I | 1 |
| Toldi, J | 10 |
| Dékány, I | 1 |
| Vécsei, L | 14 |
| Tanaka, M | 2 |
| Boros, F | 1 |
| Török, N | 1 |
| Gotina, L | 1 |
| Seo, SH | 1 |
| Kim, CW | 1 |
| Lim, SM | 1 |
| Pae, AN | 1 |
| Sandi, D | 1 |
| Fricska-Nagy, Z | 1 |
| Bencsik, K | 1 |
| Mithaiwala, MN | 1 |
| Santana-Coelho, D | 1 |
| Porter, GA | 1 |
| O'Connor, JC | 1 |
| Mor, A | 1 |
| Tankiewicz-Kwedlo, A | 1 |
| Krupa, A | 1 |
| Pawlak, D | 1 |
| Limana da Silveira, T | 1 |
| Lopes Machado, M | 1 |
| Bicca Obetine Baptista, F | 1 |
| Farina Gonçalves, D | 1 |
| Duarte Hartmann, D | 1 |
| Marafiga Cordeiro, L | 1 |
| Franzen da Silva, A | 1 |
| Lenz Dalla Corte, C | 1 |
| Aschner, M | 1 |
| Antunes Soares, FA | 1 |
| Westfall, S | 1 |
| Lomis, N | 1 |
| Kahouli, I | 1 |
| Dia, SY | 1 |
| Singh, SP | 1 |
| Prakash, S | 1 |
| Parasram, K | 1 |
| Barone, P | 1 |
| Savitz, J | 1 |
| Capucciati, A | 1 |
| Galliano, M | 1 |
| Bubacco, L | 1 |
| Zecca, L | 1 |
| Casella, L | 1 |
| Monzani, E | 1 |
| Nicolis, S | 1 |
| Amaral, M | 1 |
| Outeiro, TF | 1 |
| Scrutton, NS | 1 |
| Giorgini, F | 3 |
| Stone, TW | 3 |
| Darlington, LG | 3 |
| Maddison, DC | 1 |
| Jones, SP | 1 |
| Franco, NF | 1 |
| Varney, B | 1 |
| Sundaram, G | 1 |
| Brown, DA | 1 |
| de Bie, J | 1 |
| Brew, BJ | 1 |
| Sun, G | 1 |
| Nematollahi, A | 1 |
| Nadvi, NA | 1 |
| Kwan, AH | 1 |
| Jeffries, CM | 1 |
| Church, WB | 1 |
| Breda, C | 1 |
| Sathyasaikumar, KV | 1 |
| Sograte Idrissi, S | 1 |
| Notarangelo, FM | 1 |
| Estranero, JG | 1 |
| Moore, GG | 1 |
| Green, EW | 1 |
| Kyriacou, CP | 1 |
| Schwarcz, R | 1 |
| Zádori, D | 3 |
| Veres, G | 1 |
| Szalárdy, L | 4 |
| Klivényi, P | 5 |
| Vamos, E | 1 |
| Pardutz, A | 1 |
| Plangár, I | 2 |
| Forrest, CM | 2 |
| Massudi, H | 1 |
| Grant, R | 1 |
| Braidy, N | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Colín-González, AL | 1 |
| Maldonado, PD | 1 |
| Santamaría, A | 1 |
| Coyle, JT | 1 |
| Németh, H | 1 |
| Sas, K | 1 |
| Robotka, H | 1 |
| Khan, JA | 1 |
| Forouhar, F | 1 |
| Tao, X | 1 |
| Tong, L | 1 |
| Mackay, GM | 1 |
| Stoy, N | 1 |
| Baran, H | 1 |
| Jellinger, K | 1 |
| Deecke, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of the Nutritional Support System (NSS) on Neuromotor Alterations in Patients With Cerebral Palsy[NCT05648422] | 144 participants (Anticipated) | Interventional | 2023-01-16 | Recruiting | |||
| Investigating Brain Abnormalities in People With Knee Osteoarthritis Using MRI: a Nociplastic Pain Mechanism Based Assessment[NCT05986513] | 66 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
34 reviews available for kynurenine and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases.
Topics: Cytokines; Humans; Kynurenine; Neurodegenerative Diseases; Quinolinic Acid; Tryptophan | 2022 |
Kynurenine-3-monooxygenase (KMO): From its biological functions to therapeutic effect in diseases progression.
Topics: Disease Progression; Humans; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Neurodegenerati | 2022 |
Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases.
Topics: Aging; Animals; Huntington Disease; Kynurenine; Mammals; Models, Animal; Neurodegenerative Diseases | 2023 |
Kynurenine pathway and its role in neurologic, psychiatric, and inflammatory bowel diseases.
Topics: Humans; Inflammatory Bowel Diseases; Kynurenine; Mental Disorders; Metabolic Networks and Pathways; | 2023 |
Kynurenine pathway, NAD
Topics: Aging; Animals; Brain; Humans; Kynurenine; Longevity; Metabolic Networks and Pathways; Mice; Mitocho | 2020 |
Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Biomarkers; Cytokines; Humans; Huntington Disease; Infl | 2020 |
Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs.
Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Drug Development; Humans; Kynurenine; Neoplasms | 2020 |
Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway.
Topics: Animals; Biomarkers; Brain; Gastrointestinal Microbiome; Humans; Kynurenine; Neurodegenerative Disea | 2020 |
Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy-Kynurenines Are Important Players.
Topics: Animals; Biomarkers; Disease Progression; Humans; Kynurenine; Molecular Targeted Therapy; Multiple S | 2021 |
Neuroinflammation and the Kynurenine Pathway in CNS Disease: Molecular Mechanisms and Therapeutic Implications.
Topics: Animals; Humans; Inflammation; Kynurenine; Mental Disorders; Neurodegenerative Diseases | 2021 |
Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders.
Topics: Animals; Humans; Kynurenine; Metabolic Networks and Pathways; Metabolome; Neurodegenerative Diseases | 2021 |
Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis.
Topics: Animals; Brain; Coumaric Acids; Dysbiosis; Fatty Acids; Gastrointestinal Microbiome; Ghrelin; Histam | 2017 |
Phytochemical treatments target kynurenine pathway induced oxidative stress.
Topics: Animals; Disease Models, Animal; Glutamic Acid; Humans; Kynurenine; Neurodegenerative Diseases; Neur | 2018 |
The 'Yin' and the 'Yang' of the kynurenine pathway: excitotoxicity and neuroprotection imbalance in stress-induced disorders.
Topics: Animals; Brain; Cytokines; Depressive Disorder, Major; Excitatory Amino Acid Agents; Humans; Hypotha | 2019 |
The kynurenine pathway: a finger in every pie.
Topics: Aging; Animals; Energy Metabolism; Humans; Kynurenine; Mental Disorders; NAD; Neurodegenerative Dise | 2020 |
The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.
Topics: Animals; Humans; Kynurenine; Kynurenine 3-Monooxygenase; Neurodegenerative Diseases | 2013 |
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.
Topics: Animals; Central Nervous System; Cognition Disorders; Drugs, Investigational; Enzyme Inhibitors; Hum | 2013 |
The kynurenine pathway and neurodegenerative disease.
Topics: Animals; Humans; Kynurenine; Metabolic Networks and Pathways; Neurodegenerative Diseases; Tryptophan | 2015 |
Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).
Topics: Animals; Central Nervous System Neoplasms; Cognition Disorders; Drug Design; Enzyme Inhibitors; Huma | 2016 |
The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
Topics: Alzheimer Disease; Animals; Brain; Brain Diseases; Brain Ischemia; Epilepsy; Humans; Huntington Dise | 2009 |
Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.
Topics: Animals; Chronic Disease; Cytoprotection; Humans; Kynurenine; Mitochondria; Neurodegenerative Diseas | 2011 |
Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection.
Topics: Animals; Humans; Kynurenine; Neurodegenerative Diseases; Neuroprotective Agents; Signal Transduction | 2012 |
NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns.
Topics: Aging; Animals; Cell Death; Cell Membrane; DNA Repair; Energy Metabolism; Enzyme Activation; Humans; | 2012 |
Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects.
Topics: Animals; Chemistry, Pharmaceutical; Humans; Kynurenine; Mitochondria; Neurodegenerative Diseases; Tr | 2012 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system.
Topics: Animals; Antioxidants; Biotransformation; Central Nervous System; Humans; Kynurenine; Neurodegenerat | 2013 |
Kynurenines in the CNS: recent advances and new questions.
Topics: Animals; Autoimmune Diseases; Central Nervous System Diseases; Drug Design; Drug Evaluation, Preclin | 2013 |
Kynurenines in neurodegenerative disorders: therapeutic consideration.
Topics: AIDS Dementia Complex; Animals; Central Nervous System Diseases; Down Syndrome; Enzyme Inhibitors; H | 2004 |
Glial metabolites of tryptophan and excitotoxicity: coming unglued.
Topics: Animals; Excitatory Amino Acid Agonists; Excitatory Amino Acids; Humans; Kainic Acid; Kynurenine; Mi | 2006 |
Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.
Topics: Animals; Humans; Kynurenine; Neurodegenerative Diseases; Parkinson Disease; Quinolinic Acid; Recepto | 2006 |
Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Topics: Animals; Brain; Brain Diseases, Metabolic; Energy Metabolism; Humans; Kynurenine; Mitochondria; Mito | 2007 |
Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery.
Topics: Acrylamides; Adenosine Diphosphate Ribose; Aging; Animals; Antineoplastic Agents; Autoimmune Disease | 2007 |
Tryptophan, adenosine, neurodegeneration and neuroprotection.
Topics: Adenosine; Animals; Hepatic Encephalopathy; Humans; Kynurenine; NAD; Neurodegenerative Diseases; Neu | 2007 |
13 other studies available for kynurenine and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β.
Topics: 3-Hydroxyanthranilic Acid; Alzheimer Disease; Amyloid beta-Peptides; Australia; Biomarkers; Cognitiv | 2022 |
Analog of kynurenic acid decreases tau pathology by modulating astrogliosis in rat model for tauopathy.
Topics: Animals; Gliosis; Kynurenic Acid; Kynurenine; Neurodegenerative Diseases; Neuroprotective Agents; Ra | 2022 |
The Involvement of Kynurenine Pathway in Neurodegenerative Diseases.
Topics: Alzheimer Disease; Cross-Sectional Studies; Humans; Kynurenine; Neurodegenerative Diseases; Parkinso | 2023 |
Kynurenine and Beta-Alanine Serum Levels are Associated with the Expression of Wnt Pathway Genes in Patients with Parkinson's Disease.
Topics: Biomarkers; Humans; Kynurenine; Neurodegenerative Diseases; Parkinson Disease; Wnt Signaling Pathway | 2023 |
[Kynurenines and drug research].
Topics: Humans; Kynurenine; Migraine Disorders; Neurodegenerative Diseases | 2020 |
Pharmacophore-Based Virtual Screening of Novel Competitive Inhibitors of the Neurodegenerative Disease Target Kynurenine-3-Monooxygenase.
Topics: Blood-Brain Barrier; Brain; Computational Biology; Drug Design; Drug Evaluation, Preclinical; Enzyme | 2021 |
Caenorhabditis elegans as a model for studies on quinolinic acid-induced NMDAR-dependent glutamatergic disorders.
Topics: 1-Octanol; Adenosine Triphosphate; Amino Acid Metabolism, Inborn Errors; Animals; Animals, Genetical | 2021 |
Neuronal Proteins as Targets of 3-Hydroxykynurenine: Implications in Neurodegenerative Diseases.
Topics: alpha-Synuclein; Amyloid beta-Peptides; Cells, Cultured; Chromatography, Liquid; Humans; Kynurenine; | 2019 |
Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease.
Topics: Female; Gene Expression Regulation, Enzymologic; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynur | 2015 |
Expression, purification and crystallization of human kynurenine aminotransferase 2 exploiting a highly optimized codon set.
Topics: Chromatography, High Pressure Liquid; Codon; Escherichia coli; Gene Expression Regulation, Enzymolog | 2016 |
Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Topics: Animals; Dose-Response Relationship, Drug; Drosophila; Kynurenine; Neurodegenerative Diseases; Neuro | 2016 |
Manipulation with kynurenines: a possible tool for treating neurodegenerative diseases?
Topics: Animals; Drug Design; Humans; Kynurenic Acid; Kynurenine; Neurodegenerative Diseases; Quinolinic Aci | 2012 |
Kynurenine metabolism in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Caudate Nucleus; Female; Humans; Kinetics; Kynure | 1999 |